



Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium

Neerav Goyal, Max Hennessy, Erik Lehman, Wenxue Lin, Antonio Agudo, Wolfgang Ahrens, Stefania Boccia, Paul Brennan, Hermann Brenner, Gabriella Cadoni, et al.

► To cite this version:

Neerav Goyal, Max Hennessy, Erik Lehman, Wenxue Lin, Antonio Agudo, et al.. Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium. Oral Diseases, 2022, 10.1111/odi.14196 . hal-03712690

HAL Id: hal-03712690

<https://univ-rennes.hal.science/hal-03712690>

Submitted on 19 Jul 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

DR NEERAV GOYAL (Orcid ID : 0000-0001-7783-1097)

PROFESSOR VALERIA CARLA EDEFONTI (Orcid ID : 0000-0002-1995-1477)

DR MIA HASHIBE (Orcid ID : 0000-0002-6903-2049)

Article type : Original Article

Risk factors for head and neck cancer in more and less developed countries:

Analysis from the INHANCE Consortium

Neerav Goyal¹, Max Hennessy¹, Erik Lehman¹, Wenxue Lin¹, Antonio Agudo², Wolfgang Ahrens³, Stefania Boccia^{4a,4b}, Paul Brennan⁵, Hermann Brenner^{6a,6b,6c}, Gabriella Cadoni^{7a,7b}, Cristina Canova⁸, Chu Chen⁹, David Conway¹⁰, Maria Paula Curado¹¹, Luigino Dal Maso¹², Alexander W. Daudt¹³, Valeria Edefonti¹⁴, Eleonora Fabianova¹⁵, Leticia Fernandez¹⁶, Silvia Franceschi⁵, Werner Garavello¹⁷, Maura Gillison¹⁸, Richard B. Hayes¹⁹, Claire Healy²⁰, Rolando Herrero⁵, Ivana Holcatova²¹, Jossy L. Kanda²², Karl Kelsey²³, Bo T Hansen²⁴, Rosalina Koifman²⁵, Pagona Lagiou²⁶, Carlo La Vecchia¹⁴, Fabio Levi²⁷, Guojun Li²⁸, Jolanta Lissowska²⁹, Rossana Mendoza López³⁰, Danièle Luce³¹, Gary Macfarlane³², Dana Mates³³, Keitaro Matsuo³⁴, Michael McClean³⁵, Ana Menezes³⁶, Gwenn Menvielle³⁷, Hal Morgenstern³⁸, Kirsten Moysich³⁹, Eva Negri⁴⁰, Andrew F. Olshan⁴¹, Tamas Pandics⁴², Jerry Polesel¹², Mark Purdue⁴³, Loredana Radoi⁴⁴, Heribert Ramroth⁴⁵, Lorenzo Richiardi⁴⁶, Stimson Schantz⁴³, Stephen M. Schwartz⁹, Diego Serraino¹², Oxana Shangina⁴⁷, Elaine Smith⁴⁸, Erich M. Sturgis⁴⁹, Beata Świątkowska⁵⁰, Peter Thomson⁵¹, Thomas L. Vaughan⁹, Marta Vilensky⁵², Deborah M. Winn⁵³, Victor Wunsch-Filho⁵⁴, Guo-Pei Yu⁵⁵, Jose P. Zavallos⁵⁶, Zuo-Feng Zhang⁵⁷, Tongzhang Zheng⁵⁸, Ariana Znaor⁵, Paolo Boffetta^{59a,59b}, Mia Hashibe⁶⁰, Yuan-Chin Amy Lee⁶⁰, Joshua E Muscat¹

¹The Pennsylvania State University, College of Medicine, Hershey, PA, USA

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/ODI.14196](https://doi.org/10.1111/ODI.14196)

²Institut Catala Oncologia, Barcelona, Spain

³Leibniz Institute for Prevention Research and Epidemiology, BIPS, and University of Bremen, Faculty of Mathematics and Computer Science, Institute of Statistics, Bremen, Germany

^{4a} Sezione di Igiene, Dipartimento Universitario di Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, Italia.

^{4b} Department of Woman and Child Health and Public Health - Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia.

⁵International Agency for Research on Cancer, world Health Organization, Lyon, France

^{6a}Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany

^{6b}Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany

^{6c}German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany^{7a} Dipartimento Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy;

^{7b} Dipartimento Patologia Testa Collo e Organi di Senso, Facoltà Medicina e Chirurgia Università Cattolica Sacro Cuore, Roma, Italy;

⁸University of Padua, Padova, Italy

⁹Fred Hutchinson Cancer Research Center, Seattle, WA, USA

¹⁰Dental School, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

¹¹Epidemiology- CIPE/ACCAMARGO, Sao Paulo, Brazil

¹²Cancer Epidemiology Unit, Centro di Riferimento Oncologico (CRO) Aviano, IRCCS, Italy

¹³Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil

¹⁴Department of Clinical Sciences and Community Health, University of Milan, Italy

¹⁵Regional Authority of Public Health in Banska Bystrica, Slovakia

¹⁶Institute of Oncology and Radiobiology, Havana, Cuba

¹⁷Department of Otorhinolaryngology, School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

¹⁸Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

¹⁹Division of Epidemiology, New York University School of Medicine, New York, NY, USA

²⁰Trinity College School of Dental Science, Dublin, Ireland

- ²¹Institute of Hygiene and Epidemiology, Prague, Czech Republic
- ²²Faculdade de Medicina do ABC, Hospital de Ensino, São Bernardo do Campo, SP, Brazil
- ²³Brown University, Providence, RI, USA
- ²⁴Cancer Registry of Norway, Oslo, Norway
- ²⁵Escola Nacional de Saude Publica, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil
- ²⁶School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- ²⁷Institut Universitaire de Medecine Sociale et Preventive (IUMSP), Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
- ²⁸UT-M.D. Anderson Cancer Center, Houston, TX, USA
- ²⁹M. Sklodowska-Curie National Research Institute of Oncology, Dept. of Cancer Epidemiology and Prevention, Warsaw, Poland
- ³⁰Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, Brazil
- ³¹Univ Rennes, INSERM, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Pointe-à-Pitre, France
- ³²University of Aberdeen Dental School, Aberdeen, UK
- ³³National Institute of Public Health, Bucharest, Romania
- ³⁴Division of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
- ³⁵Boston University School of Public Health, Boston, MA, USA
- ³⁶Universidade Federal de Pelotas, Pelotas, Brazil
- ³⁷INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, F75012 Paris, France
- ³⁸Departments of Epidemiology and Environmental Health Sciences, School of Public Health and Department of Urology, Medical School, University of Michigan, Ann Arbor, MI, USA
- ³⁹Roswell Park Cancer Institute, Buffalo, NY, USA
- ⁴⁰Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
- ⁴¹University of North Carolina School of Public Health, Chapel Hill, NC, USA
- ⁴²National Public Health Center, Budapest, Hungary
- ⁴³New York Eye and Ear Infirmary, New York, NY, USA
- ⁴⁴INSERM UMR 1018, Centre for Research in Epidemiology and Population Health (CESP), Cancer Epidemiology, Genes and Environment Team, Villejuif, France
- ⁴⁵Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany
- ⁴⁶University of Turin, Turin, Italy

⁴⁷Cancer Research Centre, Moscow, Russia

⁴⁸College of Public Health, University of Iowa, Iowa City, IA, USA

⁴⁹ Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA

⁵⁰Nofer Institute of Occupational Medicine, Lodz, Poland

⁵¹University of Hong Kong, Hong Kong, China

⁵²Institute of Oncology Angel H. Roffo, University of Buenos Aires, Argentina

⁵³National Cancer Institute, Bethesda, MD, USA

⁵⁴Universidade de Sao Paulo, Sao Paulo, Brazil

⁵⁵Dept of Otolaryngology, School of Medicine, New York Medical College, Valhalla, New York

⁵⁶Division of Head and Neck Surgical Oncology in the Department of Otolaryngology/Head and Neck Surgery at Washington University School of Medicine, St. Louis, MO, USA

⁵⁷UCLA School of Public Health, Los Angeles, CA, USA

⁵⁸Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA

^{59a}Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, USA

^{59b} Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

⁶⁰Division of Public Health, Department of Family & Preventive Medicine and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA

Acknowledgements: Xavier Castellsague, Catalan Institute of Oncology. Barcelona, Spain.

Data Availability Statement: Descriptions of the studies included in the INHANCE Consortium can be found on the database website (<http://www.inhance.utah.edu>, accessed April 1, 2021).

Funding:

This work was supported by the European Community (5th Framework Programme) grant no QLK1-CT-2001-00182, INHANCE Pooled Data Project: NCI R03CA113157NIDCR R03DE016611 and the Intramural Program of the NCI, NIH, United States. Individual studies were supported by: Aviano study: Italian Association for Research on Cancer (AIRC), Italian League Against Cancer and Italian Ministry of Research; Baltimore study: NIH [DE016631]; Boston study: NIH [R01CA078609, R01CA100679], Central Europe study: World Cancer Research Fund and the European Commission INCO-COPERNICUS Program [Contract No. IC15- CT98-0332]; France 2001-2007 (ICARE): French National Research Agency (ANR); French National Cancer Institute (INCA); French Agency for Food, Environmental and Occupational Health and Safety (ANSES); French Institute for Public Health Surveillance (InVS); Fondation pour la Recherche

Médicale (FRM); Fondation de France; Fondation ARC pour la Recherche sur le Cancer; French Ministry of Labour (Direction Générale du Travail); French Ministry of Health (Direction Générale de la Santé); Germany-Heidelberg study: grant No. 01GB9702/3 from the German Ministry of Education and Research; IARC Multicenter study: Fondo de Investigaciones Sanitarias (FIS) of the Spanish Government [FIS 97/ 0024, FIS 97/0662, BAE 01/5013], International Union Against Cancer (UICC), and Yamagiwa-Yoshida Memorial International Cancer Study Grant; Iowa study: NIH [NIDCR R01DE011979, NIDCR R01DE013110, NIH FIRCA TW001500] and Veterans Affairs Merit Review Funds; Italy multicenter study: Italian Association for Research on Cancer (AIRC), Italian League Against Cancer and Italian Ministry of Research; Japan study (2001-2005): Scientific Research grant from the Ministry of Education, Science, Sports, Culture and Technology of Japan (17015052) and grant for the Third-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labor and Welfare of Japan (H20-002); Latin America study: Fondo para la Investigacion Cientifica y Tecnologica (FONCYT) Argentina, IMIM (Barcelona), Fundaco de Amparo a` Pesquisa no Estado de Sao Paulo (FAPESP) [No 01/01768-2, 04/12054-9, 10/51168-0], and European Commission [IC18-CT97-0222]; Los Angeles Study: NIH [P50CA090388, R01DA011386, R03CA077954, T32CA009142, U01CA096134, R21ES011667] and the Alper Research Program for Environmental Genomics of the UCLA Jonsson Comprehensive Cancer Center; MSKCC study: NIH [R01CA051845]; Northeast US study: NIH R01DE013158; North Carolina Study: NIH [R01CA061188], & NIEHS [P30ES010126]; NY multicenter study: NIH [P01CA068384 K07CA104231]; Milan study: Italian Association for Research on Cancer (AIRC); Puerto Rico study: jointly funded by National Institutes of Health (NCI) US and NIDCR intramural programs; Rome study: AIRC (Italian Agency for Research on Cancer); Saarland study: Ministry of Science, Research and Arts Baden-Wurttemberg; Seattle study: NIH [R01CA048996, R01DE012609]; Seattle-LEO study: NIH [R01CA030022].

Conflicts of Interest: The authors have no conflicts of interest to disclose

Ethics Approval Statement: Approval was obtained from the institutional review board at the Pennsylvania State University for use of this specific de-identified dataset.

Patient Consent Statement: Informed consent and institutional review board approval were obtained at each study center, and all identifying information was removed before data were transferred for pooling.

Corresponding Author:

Neerav Goyal, MD, MPH

The Pennsylvania State University

College of Medicine

Department of Otolaryngology-Head and Neck Surgery

500 University Drive, H091

Hershey, PA 17033-0850 USA.

Tel #: 717-531-8945

Fax #: 717-531-6160

Email: ngoyal1@pennstatehealth.psu.edu

Abstract

Objective. We analyzed the pooled case-control data from the International Head and Neck Cancer Epidemiology (INHANCE) consortium to compare cigarette smoking and alcohol consumption risk factors for head and neck cancer between less developed and more developed countries.

Subjects and Methods. The location of each study was categorized as either a less developed or more developed country. We compared the risk of overall head and neck cancer and cancer of specific anatomic subsites associated with cigarette smoking and alcohol consumption. Additionally, age and sex distribution between categories was compared.

Results. The odds ratios for head and neck cancer sites associated with smoking duration differed between less developed and more developed countries. Smoking greater than 20 years conferred a higher risk for oral cavity and laryngeal cancer in more developed countries, whereas the risk was greater for oropharynx and hypopharynx cancer in less developed countries. Alcohol consumed for more than 20 years conferred a higher risk for oropharynx, hypopharynx and larynx cancer in less developed countries. The proportion of cases that were young (<45 years) or female differed by country type for some HNC subsites.

Conclusion. These findings suggest the degree of industrialization and economic development affects the relationship between smoking-and alcohol with head and neck cancer.

Introduction

Countries can be classified as to development status based on Gross Domestic Product (GDP) per capita, which reflects availability and use of natural resources, degree of industrialization and economic development, quality and access to medical care, and social and economic development¹. On a global basis, per-capita income and economic development differ substantially between less developed and more developed countries (as defined by the United Nations), and this classification has been used as the basis for providing resources to support the economic and social development of developing countries². The World Bank has its own classification system by four gross national income groups — high, upper-middle, lower-middle, and low, where lower middle and low incomes are considered less developed countries³.

Challenges facing less developed countries include rapid urban development, outdoor and indoor air pollution control, crowding, and their associated effects on lifestyle. For example, 92% of industrial pollution-related deaths occur in low- and middle-income countries and, especially among poorer individuals in all countries⁴. Lifestyle contributions to cancer are a major concern, especially as cancer control efforts are substantially underfunded in developing countries that are experiencing aging populations and increased tobacco use in some areas. Many less developed countries lack cancer registries and other rigorously-collected health data, and determining the causes and prevention of cancer has been challenging due to the lack of resources⁵.

Head and neck cancer (HNC) is the seventh most common cancer worldwide⁶, and its incidence is increasing each year, with an estimated number of 878,348 in 2020⁷. For countries with established cancer registries, HNC rates (oral cavity, oropharynx, other HNC) increased from 1983 to 2002 in some countries but decreased in others⁸. The 2020 age-standardized rates of oral cavity cancer varied considerably by country. For example, in men the rates were 1.6 per 100,000 in Western Africa and 13.3 per 100,000 in South Central Asia⁷. It is projected that future rates will decrease with associated declines in cigarette consumption⁹.

The comparative epidemiology of HNC in less and more developed countries is not well documented¹⁰. Tobacco and alcohol use are the major risk factors worldwide, and the population attributable risk of HNC due to tobacco and alcohol in studies conducted in Europe and the Americas is 72%¹¹. Other risk factors include low fruit and vegetable intake, poor oral hygiene, hormonal factors, and occupational exposures, as well as the role of genetic variation are not fully characterized¹². Human papillomavirus (HPV) is associated primarily with oropharyngeal HNC.

To determine whether more developed and less developed countries have different risk factor profiles for HNC and HNC subsites, we used pooled data from 32 case-control studies.

The INHANCE Database

The current study included pooled datasets from the INHANCE Consortium (data version 1.5) that contained information on demographic and lifestyle characteristics, including tobacco smoking and alcohol drinking, and tumor information. Descriptions of the studies included in the INHANCE Consortium can be found on the database website (<http://www.inhance.utah.edu>, accessed April 1, 2021). The dataset for the current analysis included 32 case-control studies, most of which were age and gender frequency-matched; the study populations come from Asia, Europe, North America and South America. The pooling and harmonization methods have been previously described.^{13,14} The majority of cases were classified by ICD-9, ICD-10, or ICD-O codes. This included some cases with overlapping areas of oral cavity and pharynx, who were classified as having overlapping HNC. Informed consent and institutional review board approval were obtained at each study center, and all identifying information was removed before data were transferred for pooling. An approval was also obtained from the institutional review board at the Pennsylvania State University for use of this specific de-identified dataset. Within each study population, subject demographic information and risk factors for HNC were collected by patient questionnaire, trained interviewers, or by the subject's physicians. Data on each case's tumor characteristics were obtained from pathology records.

Variable Definitions

Smoking status variables included never, former, and current smokers. We further classified it as Ever (No) and Ever (Yes). Never smokers were classified as Ever (No). Former and current smokers were classified as Ever (Yes). The large sample size enabled us to examine ever smoking history in tumor subsites in the oral cavity and oropharynx (Table 6). For all subjects, descriptive statistics are shown in Table 1. For smoking variables, these included age started and stopped smoking, and mean duration in years. For the binary logistic regression models, duration of smoking was classified into two 20-year intervals (≤ 20 years and >20 years, Table 2). Years of alcohol consumption are shown in Table 1. Alcohol drinking duration in logistic models was also classified into two intervals (≤ 20 years and >20 years). For the variable age, it was modelled as a continuous covariate in most analyses. For table 4, because age was the variable of interest, we classified it as a binary variable (less than 45 vs. older than 45) for our analysis.

Drinking duration in models was classified into two intervals (<20 years, >20 years). Country type (location of the study) was classified as either more developed or less developed, based on United Nations classification.¹⁵ In the current study, less developed countries included Argentina, Bangladesh, Brazil, China, Cuba, Granada, India, and Sudan. More developed countries included Australia, Canada, Croatia, Greece,

France, Italy, Japan, Spain, Germany, Hungary, Poland, Romania, Russia, Slovakia, the United Kingdom and the United States.

For the main analyses, HNC was grouped into five tumor site categories: oral cavity cancer (OCC), oropharynx cancer (OPC), hypopharynx cancer (HPC), laryngeal cancer (LC), and overlapping HNC. We also conducted a descriptive analysis of smoking prevalence for just oral cavity cancer (OCC) and oropharyngeal cancer (OPC) by their subsites, to explore whether smoking history may further vary by subsite and between more developed and less developed countries.

Statistical Analysis

Descriptive statistics of subject characteristics included means and their standard deviations. Logistic regression models were fit to determine odds ratios (OR) and 95% confidence intervals (95% CI) associated with cigarette smoking years and drinking years, respectively, separately for more developed and less developed countries. In addition to the main effects, a multiplicative interaction term between each of the exposure variables (cigarette smoking years, alcohol consumption years) and country type (more vs less developed) was included in the model. The fits for models with the interaction term with country type were compared to the respective models that did not include the interaction term; the -2 log likelihoods of differences between the two models and corresponding p-values were calculated as tests of the null hypothesis of no multiplicative interaction. Due to overlap between study center and country type, it was not possible to adjust simultaneously for the former. The logistic regression analyses were therefore adjusted for geographic region where each individual study location was assigned to one of four regions (Europe, North America, Central/South America, Asia and other). The risks for HNC and its subsites were adjusted for the age (continuous), sex (categorical), and average cigarettes smoked per day (continuous). The risks associated with cigarette smoking duration were further adjusted for alcohol drinking duration but the findings were similar to the risks that were not adjusted for alcohol drinking. Due to missing data for alcohol duration in some subjects (n=8089 for developed countries, 371 for developing), final models for smoking duration are presented without adjustment for alcohol duration using the full dataset. The analysis for consumption of alcohol was conducted using the same approach, using the dichotomous indicator variable for the categories of alcohol duration to test for interaction with country type.

For the subsite analysis, cases with missing ICD subsite codes, or with codes that indicated unspecified or overlapping subsites were excluded (n=795 for developing countries and 7658 for developed countries). For this analysis, OCCs were grouped into three subcategories including: 1. Gingivo-buccal/hard palate,

retromolar; 2. Oral (anterior) tongue; 3. Floor of mouth. OPCs were subcategorized into: 1. Posterior or base of tongue, 2. Soft palate/oropharyngeal wall; 3. Tonsil. The large INHANCE database was examined for comparing the percent of ever smokers by subsite between developing and developed countries. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). Significance was set at a p-value of < 0.05 .

Results

The dataset included 25,256 cases and 36,041 controls. Table 1 shows selected characteristics of the subjects including age and sex. About 79% of cases in both groups were men. Mean and median years of smoking in cases were similar between the two groups, whereas mean years of alcohol use was 32 in less developed countries and 36 in more developed countries. Mean BMI was slightly lower in cases than controls for both developing and developed countries, which is consistent with other findings.

Smoking and alcohol on HNC

The association with more than 20 years of cigarette smoking vs. 20 years or less was increased in both more developed (OR=3.8, 95% CI 3.6-4.0) and in less developed countries (OR=2.7, 95% CI 2.4-2.9; interaction p-value < 0.0001 ; Table 2). For alcohol consumption, no differences were found by country development status (Table 3). In the case-only analysis, cases with older age (≥ 45) were more likely to be associated with developed countries (OR=1.3, 95% CI 1.1-1.4; Table 4). There was evidence of confounding by age. The crude OR was about 1.0 and the age-stratified ORs were both 1.2. The case-only OR for developed countries associated with female sex was 1.2 (95% CI 1.0-1.2; Table 5).

Oral Cavity Cancer (OCC)

The OR for OCC for 20+ years of smoking cigarettes vs ≤ 20 years was 3.3 (95% CI 3.1-3.6) in more developed countries and 2.0 (95% CI 1.8-2.2) in less developed countries (interaction p-value < 0.0001 , Table 2). The association of > 20 years of alcohol consumption was similar for less and more developed countries (Table 3). In case-only analysis, the OR for developed countries with older age (≥ 45) was 1.2 (95% CI 1.0-1.4; Table 4). The case-only OR for developed countries associated with female sex was 1.4 (95% CI 1.2-1.5; Table 5).

Oropharyngeal Cancer (OPC)

The odds ratios associated with cigarette smoking >20 years vs. ≤20 years were 5.4 (95% CI 4.4-6.7) in less developed countries and 3.3 (95% CI 3.1-3.6) in more developed countries (Table 2). The association of OPC with >20 years of alcohol use was slightly greater in less developed countries (Table 3). In case-only analysis, the odds ratio for more developed countries associated with female sex was 1.3 (95% CI 1.1-1.6; Table 5).

Hypopharyngeal Cancer (HC)

The OR associated with >20 years cigarette smoking vs. ≤20 years was 7.7 (95% CI 5.3-11.3) in less developed countries and 5.8 (95% CI 5.0-6.6) in more developed countries (interaction p-value =0.156; Table 2). The OR for longer duration of alcohol consumption was slightly higher in less developed countries (Table 3). In the case-only analysis, the odds ratio for more developed countries associated with >45 years of age was 1.9 (95% CI, 1.2-2.9, Table 4). The OR was also significantly higher for female sex (Table 5).

Laryngeal Cancer (LC)

The positive association between years of smoking cigarettes (>20 vs. <20 years) was a little stronger in more vs. less developed countries (OR=6.8 vs 4.8, interaction p-value =0.0009; Table 2). The odds ratio for longer alcohol duration was slightly higher in less developed countries (interaction p-value =0.0174; Table 3). The case-only analysis showed that the odds of being a female case were slightly higher in more developed countries (OR=1.3, 95% CI 1.1-1.5; Table 5).

Overlapping HNC

The association of smoking cigarettes >20 years vs. ≤20 years was slightly more in more developed vs. less developed countries (interaction p-value =0.021; Table 2). There was no association with alcohol consumption (Table 3, interaction p-value =0.131). In case-only analysis, age and sex were not associated with country type (Tables 4 and 5, respectively).

Case-series analysis of ever smoking by oral cavity and oropharynx subsite

Table 6 shows cigarette smoking status (ever vs. never) for more and less developed countries separately for OCC and OPC. As expected, the majority of cases for both subsites were ever smokers. The percent ever smoking was lower for cancers of the gingiva and hard palate (59% for less developed countries and 78% for more developed countries) than other subsites. The proportion of ever smoking was also lower for oral tongue (72.9% for less developed countries and 75.2% for more developed countries) compared to other cancers such as base of tongue. For floor of mouth cancer, ever smoking proportion was 89.2% in less developed countries

and 94.1% in more developed countries. Within the oropharynx, the site most commonly associated with HPV²¹, 82.1% and 83.0% of patients with base of tongue cancers were ever smokers in less and more developed countries, respectively.

Discussion

We found that the odds ratios associated with >20 years (vs ≤20 years) of cigarette smoking was greater in less developed countries for OPC and HPC, whereas >20 years cigarette smoking conferred a greater risk of OC and LC in more developed countries. In contrast, >20 years of alcohol consumption increased the odds of all HNC subsites except OC and overlapping HNC to a greater extent in less developed countries, compared to that in more developed countries.

When considering these findings, several factors need to be considered. There may be different forms or brands of cigarettes that vary by geography. Bidis (tobacco hand-wrapped in plant leaf) are cigarettes commonly used in South and Southeast Asia. They are packaged under different brand names and are often fruit-flavored. Bidis cause OC, HC and LC^{22,23}. Bidis are generally unfiltered and while they contain less tobacco than conventional cigarettes, they emit higher concentrations of tar and nicotine²⁴. INHANCE subjects who might have smoked bidi cigarettes include participants from India and Bangladesh. We did not assess the possible confounding effects of smokeless tobacco products. Chewing of betel quid or “paan” is common in parts of Asia. The areca nut is placed in a betel leaf, often in combination with smokeless tobacco products such as khaini, zarda, mawa in south-central Asia. These products have high concentrations of nitrosamines, and the OPC risk associated with betel nut chewing is about 8 fold when combined with other smokeless tobacco, and about 3 fold when used exclusively^{25,26,27}. Betel quid use information was not routinely collected in INHANCE studies from Asia. The combined association for tobacco smoking and betel quid user is difficult to assess, as betel quid chewers are mostly a subgroup of cigarette smokers in Taiwan. A recent report found no evidence of a greater association than would be expected under either a multiplicative or additive model²⁸. Data from other studies suggest an interactive effect of smoking and chewing^{27,29,30}. The OR for HNC with betel quid use in never tobacco smokers is (OR = 13.71, 95% CI 3.62, 51.92) with a greater effect possibly for OC²⁸.

Likewise, there are smokeless tobacco products used in more developed countries that are not used in less developed countries. INHANCE studies showed that except for the oral cavity, chewing tobacco in the United States was not a risk factor in never smokers and did not modify HNC risk in ever smokers³¹. Snuff use was associated with a 3-fold risk for OCC in never smokers, but only about 2% of the U.S. study population used snuff, whereas use of the more toxic smokeless product betel quid is common in some less developed populations.

The association of longer vs. shorter duration of alcohol consumption was slightly higher for larynx and pharynx cancer in less developed countries than in more developed countries. In many less developed countries, traditionally and locally prepared beverages are being replaced by internationally-marketed products, especially beer. The risk of HNC did not vary much by beverage type in a previous INHANCE study, although the analysis was limited mostly to European and North American study centers³².

BMI was lower in cases than in controls for both developing and developed countries. This is consistent with the literature. In the prospective American Cancer Society Cancer Prevention Study-II, low BMI was associated with HNC mortality but not incidence³³.

Differences in HPV infection by country type also need to be considered. The attributable fraction of HPV-associated HNC cancer (primarily OPC) has increased in more developed countries compared to less developed countries, particularly in younger men^{34 35 36}. This is in contrast to the incidence of OCC in the same populations, in which either no change or a decrease in incidence was observed, as would be expected with decreased tobacco use³⁵. Many of the INHANCE studies particularly in the more developed countries completed recruitment in the early 2000's when HPV-positive OPC was less common in more developed countries than it is today. We did not have information on HPV status in most studies and it is unclear from prior research whether there is an excess joint effect of smoking and HPV on OPC risk. Some data indicate an additive effect only, whereas other findings show that the odds ratio associated with heavy smoking is higher in subjects who are HPV seronegative than subjects who are HPV seropositive^{37,38}.

The mean age of HNC at diagnosis was slightly younger in less developed countries, consistent with another report³⁹. It has been suggested that the etiology of HNC may differ somewhat in people ages 45 and younger¹⁷. Our case-only analyses suggested that while some analyses showed departure from multiplicativity between country type and age or sex, the effect was small.

The current study did not measure other factors that are associated with a country's degree of development or developmental changes. Less developed and more developed countries are defined according to assets, wealth and industrialization. Increasing industrial pollution in less developed countries poses a substantial cancer risk including HNC, with estimates that the incidence of up to 20% of all cancers is due to environmental chemical mixtures^{40,41,42}. An increasing but still small proportion of cancer deaths in less developed countries are attributable to lifestyle changes including diet and physical inactivity, which have been associated with the risk of HNC^{43,44,45}.

The current study compares and contrasts overall and subsite-specific associations between tobacco and alcohol use and HNC risk between categories of less and more developed countries. Several INHANCE publications have employed extensive and novel statistical approaches to modeling cigarette smoking and other

exposures including spline and linear-exponential models, demonstrating further variation in risks by HNC subsite^{46,47}. The current study was not designed to recreate those analyses, but to take a first look at comparing the associations as they may vary by country development. We did not control for pipe and cigar smoking, which were previously found not to increase HNC risk in current smokers in the INHANCE data⁴⁸.

The grouping of countries by level of development is often used as a measure of health disparity, and differs from socioeconomic status (SES) groupings, which is a measure of social position within a defined geographic area⁴⁹. The SES literature shows that HNC incidence is increased in lower SES relative to higher SES populations in Western countries⁵⁰⁻⁵⁵. Using the World Bank classification system for developing and developed countries, low SES was associated with oral cancer risk in both high- and lower-income countries. In a previous INHANCE pooled analysis, low education was associated with an increased risk which that was not completely attenuated after adjusting for smoking and alcohol⁵⁶. The INHANCE consortium pooled data provided the opportunity to examine a different aspect of economic position, namely that which separates countries by wealth, assets and degree of industrialization. It should be noted that Argentina, one of the sites in the current database is classified as a less developed country, although it has an emerging economy that may be more similar to more developed countries.

While INHANCE pooled studies are unique for allowing this type of comparison, there are several limitations. While the INHANCE consortium is large and studies were conducted in many different countries, the data are not a globally representative sample. For example, there is low representation from Africa. The inclusion criteria for age across studies was not uniform, usually defined as >18 or 18-80 years for most studies. This might have biased the age analysis for the case-only comparisons. The case-only analyses are also potentially biased if assumptions of independence between country type and the exposures are violated. This approach is more often used to assess gene-environment interactions, but has potential utility in the current analysis. Misclassification is a concern in case-only analysis but the variables for the current study are well defined. Several (n=13) but not all INHANCE studies had information on oral hygiene risk factors such as tooth loss and gum disease. We were not able to adjust for these variables, although the increased risks with poor hygiene indicators in INHANCE were similar across different geographic regions in a previous report⁵⁷.

In addition, potential misclassification of HNC subsites needs to be considered when interpreting findings⁵⁸. The head and neck area is contiguous with boundaries between different sites being somewhat subjective. Some tumors are classified as overlapping but some site misclassification is described in the Surveillance, Epidemiology, and End Results (SEER) database⁵⁹.

In summary, our analyses of INHANCE data suggest that longer exposure to cigarette smoking and alcohol consumption confer somewhat higher risks among individuals from less developed countries, and

indicate the importance of sustained tobacco control efforts in both developing and developed countries. However, the success of these programs in low SES areas of some developing countries are considered to be dependent on elimination of poverty and improving social inequality⁶⁰.

References

1. Fan VY, Bloom DE, Ogbuaji O, Prettner K, Yamey G. Valuing health as development: going beyond gross domestic product. *BMJ*. 2018;363:k4371.
2. Syed SB, Dadwal V, Rutter P, et al. Developed-developing country partnerships: benefits to developed countries? *Global Health*. 2012;8:17.
3. Reynolds J. Difference between developing countries & emerging countries. 2018; <https://bizfluent.com/info-10002682-difference-between-developing-countries-emerging-countries.html>. Accessed May 20, 2019.
4. Landrigan PJ, Fuller R, Acosta NJR, et al. The Lancet Commission on pollution and health. *Lancet*. 2018;391(10119):462-512.
5. Hanna TP, Kangolle AC. Cancer control in developing countries: using health data and health services research to measure and improve access, quality and efficiency. *BMC Int Health Hum Rights*. 2010;10:24.
6. Rettig EM, D'Souza G. Epidemiology of head and neck cancer. *Surg Oncol Clin N Am*. 2015;24(3):379-396.
7. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394-424.
8. Simard EP, Torre LA, Jemal A. International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. *Oral Oncol*. 2014;50(5):387-403.
9. Lee YC, Hashibe M. Tobacco, alcohol, and cancer in low and high income countries. *Ann Glob Health*. 2014;80(5):378-383.
10. Gupta B, Johnson NW, Kumar N. Global Epidemiology of Head and Neck Cancers: A Continuing Challenge. *Oncology*. 2016;91(1):13-23.
11. Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *Cancer Epidemiol Biomarkers Prev*. 2009;18(2):541-550.

- Accepted Article
12. Bravi F, Lee YA, Hashibe M, et al. Lessons learned from the INHANCE consortium: An overview of recent results on head and neck cancer. *Oral Dis.* 2021;27(1):73-93.
 13. Hashibe M, Brennan P, Benhamou S, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *J Natl Cancer Inst.* 2007;99(10):777-789.
 14. Conway DI, Hashibe M, Boffetta P, et al. Enhancing epidemiologic research on head and neck cancer: INHANCE - The international head and neck cancer epidemiology consortium. *Oral oncology.* 2009;45(9):743-746.
 15. DESA. *World Economic Situation and Prospects 2017.* UN.
 16. Salkind NJ. *Encyclopedia of research design.* Vol 1-0. . Thousand Oaks, CA: SAGE Publications, Inc. ; 2010.
 17. Toporcov TN, Znaor A, Zhang ZF, et al. Risk factors for head and neck cancer in young adults: a pooled analysis in the INHANCE consortium. *Int J Epidemiol.* 2015;44(1):169-185.
 18. Lubin JH, Muscat J, Gaudet MM, et al. An examination of male and female odds ratios by BMI, cigarette smoking, and alcohol consumption for cancers of the oral cavity, pharynx, and larynx in pooled data from 15 case-control studies. *Cancer Causes Control.* 2011;22(9):1217-1231.
 19. Ellington TD, Henley SJ, Senkomago V, et al. Trends in Incidence of Cancers of the Oral Cavity and Pharynx - United States 2007-2016. *MMWR Morb Mortal Wkly Rep.* 2020;69(15):433-438.
 20. Radoi L, Paget-Bailly S, Cyr D, et al. Tobacco smoking, alcohol drinking and risk of oral cavity cancer by subsite: results of a French population-based case-control study, the ICARE study. *Eur J Cancer Prev.* 2013;22(3):268-276.
 21. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. *Vaccine.* 2006;24 Suppl 3:S3/11-25.
 22. Schottenfeld D, J. F. *Cancer Epidemiology and Prevention.* New York: Oxford University Press; 2008.
 23. Sapkota A, Gajalakshmi V, Jetly DH, et al. Smokeless tobacco and increased risk of hypopharyngeal and laryngeal cancers: a multicentric case-control study from India. *Int J Cancer.* 2007;121(8):1793-1798.
 24. Watson CH, Polzin GM, Calafat AM, Ashley DL. Determination of tar, nicotine, and carbon monoxide yields in the smoke of bidi cigarettes. *Nicotine Tob Res.* 2003;5(5):747-753.
 25. Stepanov I, Hecht SS, Ramakrishnan S, Gupta PC. Tobacco-specific nitrosamines in smokeless tobacco products marketed in India. *Int J Cancer.* 2005;116(1):16-19.

26. Guha N, Warnakulasuriya S, Vlaanderen J, Straif K. Betel quid chewing and the risk of oral and oropharyngeal cancers: a meta-analysis with implications for cancer control. *Int J Cancer*. 2014;135(6):1433-1443.
27. Wen CP, Tsai SP, Cheng TY, et al. Uncovering the relation between betel quid chewing and cigarette smoking in Taiwan. *Tob Control*. 2005;14 Suppl 1:i16-22.
28. Lee YA, Li S, Chen Y, et al. Tobacco smoking, alcohol drinking, betel quid chewing, and the risk of head and neck cancer in an East Asian population. *Head Neck*. 2019;41(1):92-102.
29. Liu B, Shen M, Xiong J, et al. Synergistic effects of betel quid chewing, tobacco use (in the form of cigarette smoking), and alcohol consumption on the risk of malignant transformation of oral submucous fibrosis (OSF): a case-control study in Hunan Province, China. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2015;120(3):337-345.
30. Thomas SJ, Bain CJ, Battistutta D, Ness AR, Paissat D, MacLennan R. Betel quid not containing tobacco and oral cancer: a report on a case-control study in Papua New Guinea and a meta-analysis of current evidence. *Int J Cancer*. 2007;120(6):1318-1323.
31. Wyss AB, Hashibe M, Lee YA, et al. Smokeless Tobacco Use and the Risk of Head and Neck Cancer: Pooled Analysis of US Studies in the INHANCE Consortium. *Am J Epidemiol*. 2016;184(10):703-716.
32. Purdue MP, Hashibe M, Berthiller J, et al. Type of alcoholic beverage and risk of head and neck cancer--a pooled analysis within the INHANCE Consortium. *Am J Epidemiol*. 2009;169(2):132-142.
33. Gaudet MM, Patel AV, Sun J, et al. Prospective studies of body mass index with head and neck cancer incidence and mortality. *Cancer Epidemiol Biomarkers Prev*. 2012;21(3):497-503.
34. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. *Int J Cancer*. 2017;141(4):664-670.
35. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. *J Clin Oncol*. 2013;31(36):4550-4559.
36. Enomoto LM, Bann DV, Hollenbeak CS, Goldenberg D. Trends in the Incidence of Oropharyngeal Cancers in the United States. *Otolaryngol Head Neck Surg*. 2016;154(6):1034-1040.
37. Anantharaman D, Muller DC, Laggiou P, et al. Combined effects of smoking and HPV16 in oropharyngeal cancer. *Int J Epidemiol*. 2016;45(3):752-761.

38. Smith EM, Rubenstein LM, Haugen TH, Pawlita M, Turek LP. Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. *J Oncol*. 2012;2012:571862.
39. Joshi P, Dutta S, Chaturvedi P, Nair S. Head and neck cancers in developing countries. *Rambam Maimonides Med J*. 2014;5(2):e0009.
40. <https://www.who.int/heli/risks/ehindevcoun/en/index1.html>. Accessed October 10, 2019.
41. Wong IC, Ng YK, Lui VW. Cancers of the lung, head and neck on the rise: perspectives on the genotoxicity of air pollution. *Chin J Cancer*. 2014;33(10):476-480.
42. Goodson WH, 3rd, Lowe L, Carpenter DO, et al. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. *Carcinogenesis*. 2015;36 Suppl 1:S254-296.
43. Cancer in developing countries: can the revolution begin? *Lancet Oncol*. 2011;12(3):201.
44. Platek AJ, Cannioto RA, Etter JL, et al. The association of lifetime physical inactivity with head and neck cancer: a hospital-based case-control analysis. *Eur Arch Otorhinolaryngol*. 2017;274(10):3773-3780.
45. Freedman ND, Park Y, Subar AF, et al. Fruit and vegetable intake and head and neck cancer risk in a large United States prospective cohort study. *Int J Cancer*. 2008;122(10):2330-2336.
46. Di Credico G, Edefonti V, Polesel J, et al. Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer: A bivariate spline model approach. *Oral Oncol*. 2019;94:47-57.
47. Lubin JH, Alavanja MC, Caporaso N, et al. Cigarette smoking and cancer risk: modeling total exposure and intensity. *Am J Epidemiol*. 2007;166(4):479-489.
48. Wyss A, Hashibe M, Chuang SC, et al. Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *Am J Epidemiol*. 2013;178(5):679-690.
49. Anderson C, Hildreth JAD, Howland L. Is the desire for status a fundamental human motive? A review of the empirical literature. *Psychol Bull*. 2015;141(3):574-601.
50. Al-Dakkak I. Socioeconomic status and head and neck cancer. *Evid Based Dent*. 2010;11(2):57-58.
51. Hwang E, Johnson-Obaseki S, McDonald JT, Connell C, Corsten M. Incidence of head and neck cancer and socioeconomic status in Canada from 1992 to 2007. *Oral Oncol*. 2013;49(11):1072-1076.

- Accepted Article
52. Edwards DM, Jones J. Incidence of and survival from upper aerodigestive tract cancers in the U.K.: the influence of deprivation. *Eur J Cancer*. 1999;35(6):968-972.
 53. Andersen ZJ, Lassen CF, Clemmensen IH. Social inequality and incidence of and survival from cancers of the mouth, pharynx and larynx in a population-based study in Denmark, 1994-2003. *Eur J Cancer*. 2008;44(14):1950-1961.
 54. Purkayastha M, McMahon AD, Gibson J, Conway DI. Trends of oral cavity, oropharyngeal and laryngeal cancer incidence in Scotland (1975-2012) - A socioeconomic perspective. *Oral Oncol*. 2016;61:70-75.
 55. Tataru D, Mak V, Simo R, Davies EA, Gallagher JE. Trends in the epidemiology of head and neck cancer in London. *Clin Otolaryngol*. 2017;42(1):104-114.
 56. Conway DI, Brenner DR, McMahon AD, et al. Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries. *Int J Cancer*. 2015;136(5):1125-1139.
 57. Hashim D, Sartori S, Brennan P, et al. The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. *Ann Oncol*. 2016;27(8):1619-1625.
 58. Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. *Anticancer Res*. 1998;18(6B):4779-4786.
 59. Fakhry C, Krapcho M, Eisele DW, D'Souza G. Head and neck squamous cell cancers in the United States are rare and the risk now is higher among white individuals compared with black individuals. *Cancer*. 2018;124(10):2125-2133.
 60. Kurkure AP, Yeole BB. Social inequalities in cancer with special reference to South Asian countries. *Asian Pac J Cancer Prev*. 2006;7(1):36-40.

Table 1. Selected characteristics of HNC cases and controls from less developed and more developed countries,

Characteristic	Less developed			More developed	
	Overall (n = 61,297)	Cases (n = 5,251)	Controls (n = 4,882)	Cases (n = 20,005)	Controls (n = 31,159)
Mean age (years)	58.4 ± 11.3	57.7 ± 11.1	55.4 ± 13.3	58.9 ± 10.5	58.5 ± 11.4
Sex					
Female	15410 (25.2%)	1120 (21.4%)	1601 (33.0%)	4269 (21.3%)	8420 (27.0%)
Male	45842 (74.8%)	4114 (78.6%)	3257 (67.0%)	15734 (78.7%)	22737(73.0%)
BMI (kg/m ²) *	25.1 ± 4.6	22.3 ± 4.4	24.5 ± 4.8	24.6 ± 4.7	25.8 ± 4.4
Age started smoking (years) *	18.4 ± 5.8	16.6 ± 6.1	17.5 ± 6.4	18.0 ± 5.2	19.26 ± 6.0
Age stopped smoking (years) *	50.9 ± 13.4	55.0 ± 11.1	48.1 ± 13.7	54.1 ± 12.0	47.7 ± 14.1
Duration of smoking (years) *	23.0 ± 18.9	30.4 ± 19.2	17.2 ± 19.0	31.3 ± 16.7	17.4 ± 17.6
Duration of alcohol use (years) *	33.0 ± 15.6	30.5 ± 16.2	22.4 ± 18.4	35.8 ± 14.0	33.5 ± 15.3

* mean ± standard deviation

INHANCE database

Table 2. Odds ratios for head and neck cancer subtypes by years of smoking, for more developed and less developed countries, INHANCE database

Head & Neck Cancer site	Country	Smoking Years	N (%) Cancer	Odds ratio (95% CI)	Interaction P-value*
All	More developed	≤20	4463 (19.9)	Ref	<0.0001
		>20	15334 (54.1)	3.8 (3.6, 4.0)	
	Less developed	≤20	1379 (32.8)	Ref	
		>20	3760 (65.2)	2.7 (2.4, 2.9)	
Oral cavity	More developed	≤20	1375 (7.1)	Ref	<0.0001
		>20	3614 (21.7)	3.3 (3.1, 3.6)	
	Less developed	≤20	915 (24.5)	Ref	
		>20	1226 (37.9)	2.0 (1.8, 2.2)	
Oropharynx	More developed	≤20	1422 (7.4)	Ref	<0.0001
		>20	3942 (23.2)	3.3 (3.1, 3.6)	
	Less developed	≤20	125 (4.2)	Ref	
		>20	718 (26.3)	5.4 (4.4, 6.7)	
Hypopharynx	More developed	≤20	282 (1.6)	Ref	0.1561
		>20	1618 (11.1)	5.8 (5.0, 6.6)	
	Less developed	≤20	30 (1.1)	Ref	
		>20	304 (13.2)	7.7 (5.3, 11.3)	
Larynx	More developed	≤20	662 (3.6)	Ref	0.0009
		>20	4737 (26.7)	6.8 (6.2, 7.4)	
	Less developed	≤20	160 (5.4)	Ref	
		>20	1124 (35.9)	4.8 (4.0, 5.8)	
Overlapping H&N	More developed	≤20	33 (0.2)	Ref	0.0210
		>20	142 (1.1)	4.6 (3.1, 6.8)	
	Less developed	≤20	37 (1.3)	Ref	
		>20	119 (5.6)	2.4 (1.6, 3.7)	

Adjusted for sex, age, cigarettes per day, and geographic grouping. *Interaction between smoking years and country type.

Table 3. Odds ratios for head and neck cancer subtypes by years of drinking, for more developed and less developed countries, INHANCE database

Head & Neck Cancer site	Country	Drinking Years	N (%) Cancer	Odds ratio (95% CI)	Interaction P-value*
All	More developed	≤20	3643(27.5)	Ref	0.9030
		>20	12965 (43.5)	1.7 (1.6, 1.8)	
	Less developed	≤20	1658 (38.3)	Ref	
		>20	3377 (62.1)	1.7 (1.5, 1.9)	
Oral cavity	More developed	≤20	1144 (10.6)	Ref	0.4008
		>20	3127 (15.6)	1.6 (1.5, 1.7)	
	Less developed	≤20	983 (26.9)	Ref	
		>20	1112 (35.1)	1.5 (1.5, 1.7)	
Oropharynx	More developed	≤20	948 (9.0)	Ref	0.0115
		>20	3762 (18.2)	2.0 (1.8, 2.2)	
	Less developed	≤20	197 (6.9)	Ref	
		>20	631 (23.5)	2.6 (2.1, 3.1)	
Hypopharynx	More developed	≤20	195 (2.0)	Ref	0.0240
		>20	1258 (6.9)	2.5 (2.2, 3.0)	
	Less developed	≤20	51 (1.9)	Ref	
		>20	274 (11.7)	3.8 (2.7, 5.2)	
Larynx	More developed	≤20	815 (7.8)	Ref	0.0174
		>20	3708 (18.0)	1.7 (1.5, 1.8)	
	Less developed	≤20	279 (9.5)	Ref	
		>20	976 (32.2)	2.1 (1.8, 2.4)	
Overlapping H&N	More developed	≤20	31 (0.3)	Ref	0.1313
		>20	129 (0.8)	1.4 (0.9, 2.1)	
	Less developed	≤20	28 (1.0)	Ref	
		>20	128 (5.9)	2.1 (1.4, 3.4)	

Adjusted for sex, age, cigarettes per day, and geographic grouping. *Interaction between drinking years and country type.

Table 4. Case-only odds ratios between age and more developed country status, INHANCE database

Cancer site	Age	Country Type		OR	p-value
		More developed	Less developed		
All	<45 years	1614 (8.1%)	546 (10.4%)	1.3 (1.1, 1.4)	<0.0001
	≥45 years	18391 (91.9%)	4705 (89.6%)		
Oral cavity	<45 years	501 (10.0%)	287 (13.2%)	1.2 (1.0, 1.4)	0.0216
	≥45 years	4524 (90.0%)	1887 (86.8%)		
Oropharynx	<45 years	446 (8.3%)	88 (10.2%)	1.3 (1.0, 1.7)	0.0366
	≥45 years	4951 (91.7%)	775 (89.8%)		
Hypopharynx	<45 years	97 (5.0%)	30 (8.6%)	1.9 (1.2, 2.9)	0.0042
	≥45 years	1839 (95.0%)	319 (91.4%)		
Larynx	<45 years	280 (5.1%)	71 (5.4%)	1.1 (0.8, 1.4)	0.7064
	≥45 years	5196 (94.9%)	1250 (94.6%)		
Overlapping H&N	<45 years	16 (9.1%)	21 (13.5%)	1.6 (0.8, 3.2)	0.1945
	≥45 years	159 (90.9%)	135 (86.5%)		

Adjusted for sex and cpd. OR reflects departure from multiplicativity between country type and age.

Table 5. Case-only odds ratios between sex and more developed country status, INHANCE database

Cancer site	Gender	Country Type		OR	p-value
		More developed	Less developed		
All	Male	15734 (78.7%)	4114 (78.6%)	1.2 (1.0, 1.2)	0.0006
	Female	4269 (21.3%)	1120 (21.4%)		
Oral cavity	Male	3477 (69.2%)	1484 (68.5%)	1.4 (1.2, 1.5)	<0.0001
	Female	1546 (30.8%)	681 (31.5%)		
Oropharynx	Male	4268 (79.1%)	721 (83.7%)	1.3 (1.1, 1.6)	0.0033
	Female	1129 (20.9%)	140 (16.3%)		
Hypopharynx	Male	1706 (88.2%)	318 (91.1%)	1.5 (1.0, 2.3)	0.0412
	Female	229 (11.8%)	31 (8.9%)		

Adjusted for age and cigarettes per day. OR reflects departure from multiplicativity between country type and gender.

Larynx	Male	4753 (86.8%)	1172 (89.0%)	1.3 (1.1, 1.5)	0.0152
	Female	724 (13.2%)	144 (11.0%)		
Overlapping H&N	Male	132 (75.4%)	124 (79.5%)	1.3 (0.7, 2.4)	0.3935
	Female	43 (24.6%)	32 (20.5%)		

Table 6. Ever smoking status by tumor subsite in oral cavity and oropharynx in less developed and more developed

HNC Subsite	Less developed		More developed	
	No	Yes	No	Yes
Oral cavity				
Gingivo-buccal/hard palate	400 (41.0%)	575 (59.0%)	352 (22.3%)	1226 (77.7%)
Oral tongue	191 (27.1%)	513 (72.9%)	571 (24.8%)	1734 (75.2%)
Floor of mouth	54 (10.8%)	446 (89.2%)	78 (5.9%)	1246 (94.1%)
Oropharynx				
Base of tongue	64 (17.9%)	293 (82.1%)	188 (17.0%)	917 (83.0%)
Soft palate/ oropharyngeal wall	15 (6.6%)	212 (93.4%)	90 (8.8%)	938 (91.2%)
Tonsil	34 (11.6%)	258 (88.4%)	230 (15.0%)	1311 (85.0%)

countries, INHANCE database

Excludes sites not otherwise specified.